Patents by Inventor Paul Bryan Wren

Paul Bryan Wren has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL USE
    Publication number: 20240173290
    Abstract: The present disclosure relates to an inhibitor of human TRPM3 for use in the treatment or prevention of migraine. Combination therapies are also described. In other aspects, the present disclosure provides methods for identifying suitable patients, methods for identifying inhibitors of human TRPM3 and cell lines for use in such methods.
    Type: Application
    Filed: January 12, 2022
    Publication date: May 30, 2024
    Applicants: GlaxoSmithKline Intellectual Property (No.3) Limited, 23andMe, Inc.
    Inventors: Janet Mary KUMAR, Colin Houston McPHEE, Adam Mohamed NAGUIB, Lea SAROV-BLAT, Claire Yvonne Marie TOWNSEND, Paul Bryan WREN, Clint Emest YOUNG
  • NOVEL USE
    Publication number: 20230220037
    Abstract: The present disclosure relates to an inhibitor of human TRPM3 for use in the treatment or prevention of migraine, including in subjects whose migraines are not responsive to CGRP inhibition or whose migraines are responsive to triptans. Combination therapies are also described. In other aspects, the present disclosure provides methods for identifying suitable patients, methods for identifying inhibitors of human TRPM3, cell lines and agonists for use in such methods and a method for measuring PACAP release.
    Type: Application
    Filed: July 13, 2022
    Publication date: July 13, 2023
    Applicants: GlaxoSmithKline Intellectual Property (No.3) Limited, 23andMe, Inc.
    Inventors: Janet Mary KUMAR, Colin Houston McPHEE, Adam Mohamed NAGUIB, Lea SAROV-BLAT, Claire Yvonne Marie TOWNSEND, Paul Bryan WREN, Clint Ernest YOUNG, Alexander George Steven PRESTON, David Andrew HALL
  • 1-(cyclopent-2-en-1-yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as CXCR2 inhibitors
    Patent number: 10336719
    Abstract: The invention relates to 1-(3-sulfonylphenyl)-3-(cyclopent-2-en-1-yl)urea derivatives, and their use in treating or preventing diseases and conditions mediated by the CXCR2 receptor. In addition, the invention relates to compositions containing the derivatives and processes for their preparation.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: July 2, 2019
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Weichun Chen, Ebere F Igboko, Xichen Lin, Hongfu Lu, Feng Ren, Paul Bryan Wren, Zhongmiao Xu, Ting Yang, Lindong Zhu
  • Novel Compounds
    Publication number: 20190010135
    Abstract: The invention relates to 1-(3-sulfonylphenyl)-3-(cyclopent-2-en-1-yl)urea derivatives, and their use in treating or preventing diseases and conditions mediated by the CXCR2 receptor. In addition, the invention relates to compositions containing the derivatives and processes for their preparation.
    Type: Application
    Filed: September 13, 2018
    Publication date: January 10, 2019
    Inventors: Weichun Chen, Ebere F. Igboko, Xichen Lin, Hongfu Lu, Feng Ren, Paul Bryan Wren, Zhongmiao Xu, Ting Yang, Lindong Zhu
  • 1-(cyclopent-2-en-1-yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as CXCR2 inhibitors
    Patent number: 10106515
    Abstract: The invention relates to 1-(3-sulfonylphenyl)-3-(cyclopent-2-en-1-yl)urea derivatives, and their use in treating or preventing diseases and conditions mediated by the CXCR2 receptor In addition, the invention relates to compositions containing the derivatives and processes for their preparation.
    Type: Grant
    Filed: May 27, 2015
    Date of Patent: October 23, 2018
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Weichun Chen, Ebere F Igboko, Xichen Lin, Hongfu Lu, Feng Ren, Paul Bryan Wren, Zhongmiao Xu, Ting Yang, Lingdong Zhu
  • Use of CXCR2 Antagonists For The Prevention and/or Treatment of Chemotherapy Induced Peripheral Neuropathy (CIPN)
    Publication number: 20170224679
    Abstract: The invention relates to the use of a CXCR2 antagonist for the prevention and/or treatment of chemotherapy induced peripheral neuropathy (CIPN).
    Type: Application
    Filed: July 27, 2015
    Publication date: August 10, 2017
    Inventors: Ebere F. IGBOKO, Paul Bryan WREN
  • 1-(CYCLOPENT-2-EN-1-YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS
    Publication number: 20170190681
    Abstract: The invention relates to 1-(3-sulfonylphenyl)-3-(cyclopent-2-en-1-yl)urea derivatives, and their use in treating or preventing diseases and conditions mediated by the CXCR2 receptor In addition, the invention relates to compositions containing the derivatives and processes for their preparation
    Type: Application
    Filed: May 27, 2015
    Publication date: July 6, 2017
    Applicant: Glaxosmithline Intellectual Property Development Limited
    Inventors: Weichun CHEN, Ebere F. IGBOKO, Xichen LIN, Hongfu LU, Feng REN, Paul Bryan WREN, Zhongmiao XU, Ting YANG, Lingdong ZHU
  • Use of a p38 kinase inhibitor for treating psychiatric disorders
    Patent number: 7989479
    Abstract: The use of 6-(S-Cyclopropylcarbamoyl-S-fluoro-2-methyl-phenyl)-N-(2,2-dimethylproyl)-nicotinamide, which is known in the art as a p38 kinase inhibitor in the treatment or prophlaxis of one or more psychiatric disorders.
    Type: Grant
    Filed: June 13, 2007
    Date of Patent: August 2, 2011
    Assignee: GlaxoSmithKline LLC
    Inventors: Mauro Corsi, Isidore Faiferman, Emilio Merlo Pich, Emiliangelo Ratti, Paul Bryan Wren
  • Novel Compounds
    Publication number: 20100144755
    Abstract: Novel substituted 2,4,8-trisubstituted 8H-pyrido[2,3-d]pyrimidin-7-one containing compounds and compositions, and their use use in therapy as CSBP/RK/p38 kinase inhibitors.
    Type: Application
    Filed: June 15, 2007
    Publication date: June 10, 2010
    Applicant: Glaxo Group Limited
    Inventors: Mauro Corsi, Isidore Faiferman, Emilio Merlo-Pich, Emiliangelo Ratti, Paul Bryan Wren
  • "NOVEL COMPOUNDS"
    Publication number: 20100069409
    Abstract: Novel substituted 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds, and 1,5,7-trisubstituted-3,4-dihydro-pyrimido[4,5-d]pyrimidin-2-(M)-one compounds and compositions, and their use in therapy as CSBP/RK/p38 kinase inhibitors.
    Type: Application
    Filed: June 15, 2007
    Publication date: March 18, 2010
    Applicant: GLAXO GROUP LIMITED
    Inventors: Mauro Corsi, Isidore Faiferman, Emilio Merlo-Pich, Emiliangelo Ratti, Paul Bryan Wren
  • Use of a p38 Kinase Inhibitor for Treating Psychiatric Disorders
    Publication number: 20100016377
    Abstract: The use of 6-(S-Cyclopropylcarbamoyl-S-fluoro-2-methyl-phenyl)-N-(2,2-dimethylproyl)-nicotinamide, which is known in the art as a p38 kinase inhibitor in the treatment or prophlaxis of one or more psychiatric disorders.
    Type: Application
    Filed: June 13, 2007
    Publication date: January 21, 2010
    Inventors: Mauro Corsi, Isidore Faiferman, Emilio Merlo Pich, Emiliangelo Ratti, Paul Bryan Wren
  • NOVEL COMPOUNDS
    Publication number: 20090318424
    Abstract: Novel substituted 1,5,7-trisubstituted-3,4-dihydro-pyrimido[4,5-d]pyrimidin-2-(1H)-one compounds and compositions, and their use in therapy as CSBP/RK/p38 kinase inhibitors.
    Type: Application
    Filed: June 15, 2007
    Publication date: December 24, 2009
    Inventors: Mauro Corsi, Isidore Faiferman, Emilio Merlo-Pich, Emiliangelo Ratti, Paul Bryan Wren